Randomized trial of bevacizumab in advanced renal cell carcinoma

被引：0
|
作者：
Ronald M. Bukowski
机构：
来源：
Current Oncology Reports | 2008年 / 10卷
关键词：
Renal Cell Carcinoma; Bevacizumab; Clin Oncol; Sorafenib; Erlotinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：99 / 100
页数：1
相关论文
共 50 条
  • [21] Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma
    Voss, Martin H.
    Molina, Ana M.
    Chen, Ying-Bei
    Woo, Kaitlin M.
    Chaim, Joshua L.
    Coskey, Devyn T.
    Redzematovic, Almedina
    Wang, Patricia
    Lee, William
    Selcuklu, S. Duygu
    Lee, Chung-Han
    Berger, Michael F.
    Tickoo, Satish K.
    Reuter, Victor E.
    Patil, Sujata
    Hsieh, James J.
    Motzer, Robert J.
    Feldman, Darren R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (32) : 3846 - +
  • [22] Randomized phase iii trial of sorafenib in advanced renal cell carcinoma (RCC): Iimpact of crossover on survival
    Eisen, T.
    Bukowski, R.
    Staehler, M.
    Szczylik, C.
    S., Oudard
    Stadler, W.
    Simantov, R.
    Shan, M.
    Escudier, B.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 237 - 237
  • [23] Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival
    Eisen, T.
    Bukowski, R. M.
    Staehler, M.
    Szczylik, C.
    Oudard, S.
    Stadler, W. M.
    Schwartz, B.
    Simantov, R.
    Shan, M.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2006, 17 : 54 - 54
  • [24] FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma
    Summers, Jeff
    Cohen, Martin H.
    Keegan, Patricia
    Pazdur, Richard
    ONCOLOGIST, 2010, 15 (01): : 104 - 111
  • [25] A pharmacodynamic trial of sequential sunitinib (Su) with bevacizumab (Bev) in patients (Pts) with renal cell carcinoma and other advanced solid malignancies
    Bruce, Justine Yang
    Hammers, Hans
    Kolesar, Jill
    Stein, Mark N.
    Eickhoff, Jens C.
    Carmichael, Lakeesha
    Johnston, Susan
    Perlman, Scott
    Jeraj, Robert
    Liu, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [26] Phase II clinical trial of bevacizumab plus ixabepilone in renal cell carcinoma.
    Pichun, Mauricio Emmanuel Burotto
    Acquavella, Nicolas
    Edgerly, Maureen
    Bates, Susan Elaine
    Balasubramaniam, Sanjeeve
    Fojo, Antonio Tito
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [27] Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma
    Maiti, Abhishek
    Nemati-Shafaee, Maryam
    Msaouel, Pavlos
    Pagliaro, Lance C.
    Jonasch, Eric
    Tannir, Nizar M.
    Shah, Amishi Y.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (01) : E47 - E57
  • [28] Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma
    Feldman, D. R.
    Ginsberg, M. S.
    Baum, M.
    Flombaum, C.
    Hassoun, H.
    Velasco, S.
    Fischer, P.
    Ishill, N. M.
    Ronnen, E. A.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs
    Lee, Chung-Han
    Hoetker, Andreas M.
    Voss, Martin H.
    Feldman, Darren R.
    Woo, Kaitlin M.
    Patil, Sujata
    Coskey, Devyn T.
    Akin, Oguz
    Hsieh, James J.
    Motzer, Robert J.
    CLINICAL GENITOURINARY CANCER, 2016, 14 (01) : 56 - 62
  • [30] Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival.
    Eisen, T.
    Bukowski, R. M.
    Staehler, M.
    Szczylik, C.
    Oudard, S.
    Stadler, W. M.
    Schwartz, B.
    Simantov, R.
    Shan, M.
    Escudier, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 223S - 223S
12345